In this randomized clinical trial among critically ill patients hospitalized for COVID-19, an initial strategy of P2Y12 inhibition did not result in a higher probability of survival to hospital discharge or a greater number of days free of cardiovascular or respiratory organ support. The gene discussed is P2RY12; the disease is COVID-19.